Approval · Notice of Compliance 22685 · 2019
DAPTOMYCIN FOR INJECTION: Notice of Compliance 22685
Issued September 25, 2019
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 22685
- Date
- September 25, 2019
- Company
- Pfizer Canada UlcKirkland, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Other
- Canadian reference product
- CUBICIN (Cubist Pharmaceuticals Llc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| DAPTOMYCIN FOR INJECTION | 02460009 | Cancelled Pre Market |
| DAPTOMYCIN FOR INJECTION | 02460017 | Cancelled Pre Market |
Medicinal ingredients
- DAPTOMYCIN 350 MG per VIAL
- DAPTOMYCIN 500 MG per VIAL